CAMBRIDGE, Mass., Dec. 11, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (NasdaqGM:INFI - News) today announced that it has reacquired from MedImmune, a unit of AstraZeneca, all worldwide development and commercialization rights to its heat shock protein 90 (Hsp90) inhibitor program. Infinity’s Hsp90 program comprises IPI-504 (retaspimycin hydrochloride for injection) and oral IPI-493. IPI-504 is in several clinical trials, including an international Phase 3 registration trial for patients with refractory gastrointestinal stromal tumors (the RING trial), positioning it as the potential first-to-market Hsp90 inhibitor. Oral IPI-493 is currently in a Phase 1 study in patients with advanced solid tumors.
